Literature DB >> 23651795

Morphine dependence and withdrawal induced changes in cholinergic signaling.

Nichole M Neugebauer1, Emily B Einstein, Maria B Lopez, Tristan D McClure-Begley, Yann S Mineur, Marina R Picciotto.   

Abstract

Cholinergic signaling is thought to be involved in morphine dependence and withdrawal, but the specific mechanisms involved remain unclear. The current study aimed to identify alterations in the cholinergic system that may contribute to the development of morphine dependence and withdrawal. Acetylcholinesterase (AChE) activity and [³H]-epibatidine binding were evaluated in order to determine if morphine dependence and withdrawal induces alterations in cholinergic signaling or expression of high affinity nicotinic acetylcholine receptors (nAChRs) in the midbrain (MB), medial habenula (MHb) and interpeduncular nucleus (IPN). The effect of cholinergic signaling through nAChRs on morphine-withdrawal induced jumping behavior was then determined. Lastly, the contribution of β4-containing nAChRs receptors in the MHb to morphine-withdrawal induced jumping behavior and neuronal activity as indicated by c-fos expression was assessed. Chronic morphine administration decreased AChE activity in MB and MHb, an effect that was no longer present following precipitated withdrawal. Morphine dependent mice showed increased nicotinic acetylcholine receptor (nAChR) levels in MB. Further, nicotine (0.4 mg/kg) and lobeline (3 mg/kg) decreased jumping behavior while mecamylamine (1 mg/kg) had no effect. Knock-down of β4 subunit-containing nAChRs in the MHb attenuated c-fos activation, but did not decrease morphine withdrawal-induced jumping. Thus, morphine withdrawal induces cholinergic signaling in the MHb, but this does not appear to be responsible for the effects of cholinergic drugs on somatic signs of opiate withdrawal, as measured by jumping behavior.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651795      PMCID: PMC3690589          DOI: 10.1016/j.pbb.2013.04.015

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  51 in total

Review 1.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Authors:  Linda P Dwoskin; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2002-01-15       Impact factor: 5.858

2.  Heterogeneity and selective targeting of neuronal nicotinic acetylcholine receptor (nAChR) subtypes expressed on retinal afferents of the superior colliculus and lateral geniculate nucleus: identification of a new native nAChR subtype alpha3beta2(alpha5 or beta3) enriched in retinocollicular afferents.

Authors:  Cecilia Gotti; Milena Moretti; Alessio Zanardi; Annalisa Gaimarri; Nicolas Champtiaux; Jean-Pierre Changeux; Paul Whiteaker; Michael J Marks; Francesco Clementi; Michele Zoli
Journal:  Mol Pharmacol       Date:  2005-07-27       Impact factor: 4.436

3.  Modification of precipitated morphine and methadone abstinence in mice by acetylcholine antagonists.

Authors:  K Jhamandas; G Dickinson
Journal:  Nat New Biol       Date:  1973-10-17

4.  Acetylcholinesterase fluctuations in the brain of mice during morphine dependence development, withdrawal and naloxone induced withdrawal.

Authors:  P P Sood; K P Mohanakumar
Journal:  Cell Mol Biol       Date:  1985       Impact factor: 1.770

5.  Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.

Authors:  Cecilia Gotti; Milena Moretti; Francesco Clementi; Loredana Riganti; J Michael McIntosh; Allan C Collins; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2005-03-04       Impact factor: 4.436

6.  Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice.

Authors:  Ramiro Salas; Renea Sturm; Jim Boulter; Mariella De Biasi
Journal:  J Neurosci       Date:  2009-03-11       Impact factor: 6.167

Review 7.  Neural substrates of opiate withdrawal.

Authors:  G F Koob; R Maldonado; L Stinus
Journal:  Trends Neurosci       Date:  1992-05       Impact factor: 13.837

8.  Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.

Authors:  Sharon R Grady; Milena Moretti; Michele Zoli; Michael J Marks; Alessio Zanardi; Luca Pucci; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

9.  Morphine-induced changes in acetylcholine release in the interpeduncular nucleus and relationship to changes in motor behavior in rats.

Authors:  Olga D Taraschenko; Heather Y Rubbinaccio; Joseph M Shulan; Stanley D Glick; Isabelle M Maisonneuve
Journal:  Neuropharmacology       Date:  2007-04-29       Impact factor: 5.250

10.  New acetylcholinesterase inhibitors for Alzheimer's disease.

Authors:  Mona Mehta; Abdu Adem; Marwan Sabbagh
Journal:  Int J Alzheimers Dis       Date:  2011-12-15
View more
  19 in total

1.  The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies.

Authors:  P P Muldoon; K J Jackson; E Perez; J L Harenza; S Molas; B Rais; H Anwar; N T Zaveri; R Maldonado; U Maskos; J M McIntosh; M Dierssen; M F Miles; X Chen; M De Biasi; M I Damaj
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 2.  Interactions between nicotine and drugs of abuse: a review of preclinical findings.

Authors:  Stephen J Kohut
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-02       Impact factor: 3.829

3.  Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by modulating P65 and TRAF6.

Authors:  Shuwei Qiu; Yimin Feng; Gene LeSage; Ying Zhang; Charles Stuart; Lei He; Yi Li; Yi Caudle; Ying Peng; Deling Yin
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

4.  Chronic Nicotine Exposure Alters the Neurophysiology of Habenulo-Interpeduncular Circuitry.

Authors:  Matthew C Arvin; Xiao-Tao Jin; Yijin Yan; Yong Wang; Matthew D Ramsey; Veronica J Kim; Nicole A Beckley; Brittany A Henry; Ryan M Drenan
Journal:  J Neurosci       Date:  2019-03-13       Impact factor: 6.167

5.  Mu opioid receptors in the medial habenula contribute to naloxone aversion.

Authors:  L J Boulos; S Ben Hamida; J Bailly; M Maitra; A T Ehrlich; C Gavériaux-Ruff; E Darcq; B L Kieffer
Journal:  Neuropsychopharmacology       Date:  2019-04-20       Impact factor: 7.853

Review 6.  Translating the Habenula-From Rodents to Humans.

Authors:  Laura-Joy Boulos; Emmanuel Darcq; Brigitte Lina Kieffer
Journal:  Biol Psychiatry       Date:  2016-06-07       Impact factor: 13.382

7.  Enhanced Sensitivity of α3β4 Nicotinic Receptors in Enteric Neurons after Long-Term Morphine: Implication for Opioid-Induced Constipation.

Authors:  Aravind R Gade; Minho Kang; Fayez Khan; John R Grider; M Imad Damaj; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2016-04-11       Impact factor: 4.030

Review 8.  The Cholinergic System as a Treatment Target for Opioid Use Disorder.

Authors:  Kevin P Jensen; Elise E DeVito; Sarah Yip; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 9.  Linking the CHRNA5 SNP to drug abuse liability: From circuitry to cellular mechanisms.

Authors:  Julia K Brynildsen; Julie A Blendy
Journal:  Neuropharmacology       Date:  2021-02-01       Impact factor: 5.250

Review 10.  [The roles of habenula and related neural circuits in neuropsychiatric diseases].

Authors:  Yuxing Wu; Shihong Zhang; Zhong Chen
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.